Zydus Lifesciences Ltd Analyst Rating
based on 32 analysts
35.48%
Buy
32.26%
Hold
32.26%
Sell
Based on 32 analysts offering long term price targets for Zydus Lifesciences Ltd. An average target of ₹1168.69
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Share analysis
Zydus Lifesciences Ltd price forecast by 32 analysts
Upside of20.76%
High
₹1496
Target
₹1168.69
Low
₹816
Zydus Lifesciences Ltd target price ₹1168.69, a slight upside of 20.76% compared to current price of ₹949.75. According to 32 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.27%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences Ltd EPS growth forecast
EPS estimate Q1, FY2026:23.72%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Performance
Day's Low
Day's High
₹933₹99052 Week's Low
52 Week's High
₹606.05₹1,324.3
| Returns % | |
| 1 Month Return | -8.9 % |
| 3 Month Return | -22.6 % |
| 1 Year Return | + 55.25 % |
| Market Stats | |
| Previous Close | ₹967.75 |
| Open | ₹970.00 |
| Volume | 30.08L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹97,378.29Cr |
Zydus Lifesciences Ltd Key Statistics
| P/E Ratio | 23.31 |
| PEG Ratio | 1.41 |
| Market Cap | ₹97,378.29 Cr |
| P/B Ratio | 6.43 |
| EPS | 38.31 |
| Dividend Yield | 0.3 |
| Sector | Pharmaceuticals |
| ROE | 23.45 |
Zydus Lifesciences Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹97,378.29 Cr | 66.12% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹14,604.82 Cr | -0.61% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹75,530.42 Cr | 39.42% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹61,039.14 Cr | 28.71% | 0.53 | NA | NA | |
| BUY | ₹43,017.27 Cr | 11.65% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences Ltd
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Share Price: ₹949.75 per share as on 12 Nov, 2024 04:01 PM
Market Capitalisation: ₹97,378.29Cr as of today
Revenue: ₹5,113.60Cr as on September 2024 (Q3 24)
Net Profit: ₹898.10Cr as on September 2024 (Q3 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Acquires Stake in Mylab - 12 Nov, 2024
Zydus Lifesciences, through its subsidiary Zydus Animal Health and Investments, will acquire a 6.5% stake in Mylab Discovery Solutions from Rising Sun Holdings.
Zydus Lifesciences Gains WHO Approval for Vaccine - 23 Oct, 2024
Zydus Lifesciences Limited's ZyVac TCV vaccine received in-principle approval from WHO, allowing it to be procured by UN agencies, boosting stock prices significantly.
Zydus Lifesciences Secures USFDA Approval for Drug - 18 Oct, 2024
Zydus Lifesciences announced final USFDA approval for Fludrocortisone Acetate tablets, a significant milestone. The drug generated $19.9 million in annual sales in the U.S. Shares rose 1% following the news.
Zydus Receives FDA Approval Amid Market Challenges - 17 Oct, 2024
Zydus Lifesciences has received FDA approval for Fludrocortisone Acetate tablets, while Macquarie maintains an Outperform rating with a target price of Rs 1,365, citing concerns over gCabometyx patent issues.
Zydus Lifesciences Shares Drop After Patent Ruling - 16 Oct, 2024
Zydus Lifesciences shares fell nearly 3% following a U.S. federal judge's ruling favoring Exelixis in a patent dispute over Cabometyx. MSN Laboratories, in partnership with Zydus, admitted its generic version infringed on Exelixis patents, delaying its launch until January 2030.
Zydus Initiates Phase 2 Trials for Desidustat - 15 Oct, 2024
Zydus Lifesciences has partnered with ICMR to initiate Phase 2 clinical trials of Desidustat oral tablet for treating sickle cell disease, evaluating its efficacy and safety.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.59% to 7.52% in Sep 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.80% to 6.85% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.8% return, outperforming this stock by 29.3%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 67.8% return, outperforming this stock by 12.5%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 1.41K Cr → 911.2 Cr (in ₹), with an average decrease of 35.8% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, ZYDUSLIFE stock has moved down by -22.6%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 6.27K Cr → 5.30K Cr (in ₹), with an average decrease of 15.4% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 7.24% to 6.57% in Sep 2024 quarter
Zydus Lifesciences Ltd Financials
Index Inclusions
Zydus Lifesciences Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 7.52% | 34.61 | |
| Mutual Funds | 6.57% | ||
| Retail Investors | 6.85% | 0.71 | |
| Others | 4.08% |
Zydus Lifesciences Ltd Key Indicators
Zydus Lifesciences Ltd Valuation
Zydus Lifesciences Ltd in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (23.31x)
November 11, 2024
Industry (56.74x)
November 11, 2024
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Ltd Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 30.64% since last year same period to ₹1,419.90Cr in the Q1 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 20.1% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.93%.
Read More about Dividends
Zydus Lifesciences Ltd Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Zydus Lifesciences Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Zydus Lifesciences Ltd shares.
Zydus Lifesciences Ltd (ZYDUSLIFE) share price today is ₹949.75
Zydus Lifesciences Ltd is listed on NSE
Zydus Lifesciences Ltd is listed on BSE
- Today’s highest price of Zydus Lifesciences Ltd is ₹990.
- Today’s lowest price of Zydus Lifesciences Ltd is ₹933.
PE Ratio of Zydus Lifesciences Ltd is 23.31
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share
Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 30.08L.
Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹97378.29Cr.
| Zydus Lifesciences Ltd(ZYDUSLIFE | Price |
|---|---|
52 Week High | ₹1324.3 |
52 Week Low | ₹606.05 |
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹949.75. It is down -28.28% from its 52 Week High price of ₹1324.3
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹949.75. It is up 56.71% from its 52 Week Low price of ₹606.05
| Zydus Lifesciences Ltd(ZYDUSLIFE | Returns |
|---|---|
1 Day Returns | -18% |
1 Month Returns | -8.9% |
3 Month Returns | -22.6% |
1 Year Returns | 55.25% |